Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Subscribe To Our Newsletter & Stay Updated
